Reviews citing this publication (8)
- Advances in the development of hybrid anticancer drugs. Fortin S, Bérubé G. Expert Opin Drug Discov 8 1029-1047 (2013)
- Vitamin D in cancer chemoprevention. Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimannno M, Flandina C, Tumminello FM, Leto G. Pharm Biol 53 1399-1434 (2015)
- Epigenetic polypharmacology: from combination therapy to multitargeted drugs. de Lera AR, Ganesan A. Clin Epigenetics 8 105 (2016)
- Vitamin D and Its Synthetic Analogs. Maestro MA, Molnár F, Carlberg C. J Med Chem 62 6854-6875 (2019)
- Multitarget Drugs: an Epigenetic Epiphany. Ganesan A. ChemMedChem 11 1227-1241 (2016)
- Structural considerations of vitamin D signaling. Molnár F. Front Physiol 5 191 (2014)
- Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators. Yamada S, Makishima M. Trends Pharmacol Sci 35 324-337 (2014)
- The Centennial Collection of VDR Ligands: Metabolites, Analogs, Hybrids and Non-Secosteroidal Ligands. Maestro MA, Seoane S. Nutrients 14 4927 (2022)
Articles citing this publication (5)
- A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy. Patel HK, Siklos MI, Abdelkarim H, Mendonca EL, Vaidya A, Petukhov PA, Thatcher GR. ChemMedChem 9 602-613 (2014)
- Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. Bijian K, Kaldre D, Wang TT, Su J, Bouttier M, Boucher A, Alaoui-Jamali M, White JH, Gleason JL. J Steroid Biochem Mol Biol 177 135-139 (2018)
- Editorial Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment. Papavassiliou KA, Papavassiliou AG. Expert Opin Investig Drugs 23 291-294 (2014)
- Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids. Kaldre D, Wang TT, Fischer J, White JH, Gleason JL. Bioorg Med Chem 23 5035-5049 (2015)
- Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer. Barbier C, Mansour A, Ismailova A, Sarmadi F, Scarlata DA, Bouttier M, Zeitouni C, Wang C, Gleason JL, White JH. Sci Rep 12 6745 (2022)